IL33 and melanoma: In marked contrast, when ST2−/− spleen cells were assayed in the chip for their migratory response to treated melanoma cells, no significant displacement was observed towards either right (DAC/IL-33) or left (single treatment or no treatment) melanoma chambers (Fig. 6C-D).